Genocea Biosciences (GNCA) Misses Q1 EPS by 6c

Genocea Biosciences (NASDAQ: GNCA) reported Q1 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15).

“2018 has been an exciting year for Genocea,” said Chip Clark, president and chief executive officer of the company. “Following our January financing, we are funded to advance our lead neoantigen cancer vaccine candidate GEN-009 into clinical trials later this year, and to continue to generate and present scientific data further elaborating on the ability of our ATLAS platform to identify and characterize neoantigens for use in cancer vaccines.”

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
• Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
• SpaceX's spectrum deal puts SIRI's satellite assets in focus